Alpine Immune Sciences, Inc.

DB:34LA Stock Report

Market Cap: €4.1b

Alpine Immune Sciences Management

Management criteria checks 3/4

Alpine Immune Sciences' CEO is Mitch Gold, appointed in Jun 2016, has a tenure of 7.92 years. total yearly compensation is $2.92M, comprised of 20.5% salary and 79.5% bonuses, including company stock and options. directly owns 0.019% of the company’s shares, worth €791.58K. The average tenure of the management team and the board of directors is 4.3 years and 6.1 years respectively.

Key information

Mitch Gold

Chief executive officer

US$2.9m

Total compensation

CEO salary percentage20.5%
CEO tenure7.9yrs
CEO ownership0.02%
Management average tenure4.3yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mitch Gold's remuneration changed compared to Alpine Immune Sciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-US$37m

Dec 31 2023US$3mUS$599k

-US$32m

Sep 30 2023n/an/a

-US$57m

Jun 30 2023n/an/a

-US$59m

Mar 31 2023n/an/a

-US$64m

Dec 31 2022US$3mUS$544k

-US$58m

Sep 30 2022n/an/a

-US$54m

Jun 30 2022n/an/a

-US$54m

Mar 31 2022n/an/a

-US$47m

Dec 31 2021US$3mUS$523k

-US$50m

Sep 30 2021n/an/a

-US$42m

Jun 30 2021n/an/a

-US$34m

Mar 31 2021n/an/a

-US$33m

Dec 31 2020US$1mUS$500k

-US$28m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$33m

Mar 31 2020n/an/a

-US$35m

Dec 31 2019US$2mUS$485k

-US$42m

Sep 30 2019n/an/a

-US$47m

Jun 30 2019n/an/a

-US$48m

Mar 31 2019n/an/a

-US$44m

Dec 31 2018US$1mUS$400k

-US$36m

Sep 30 2018n/an/a

-US$30m

Jun 30 2018n/an/a

-US$15m

Mar 31 2018n/an/a

-US$11m

Dec 31 2017US$2mUS$300k

-US$8m

Compensation vs Market: Mitch's total compensation ($USD2.92M) is about average for companies of similar size in the German market ($USD2.36M).

Compensation vs Earnings: Mitch's compensation has increased whilst the company is unprofitable.

CEO

Mitch Gold (55 yo)

7.9yrs

Tenure

US$2,921,224

Compensation

Dr. Mitchell H. Gold, also known as Mitch, M.D., has been Executive Chairman and Chief Executive Officer at Alpine Immune Sciences Inc. since January 2015 and June 2016 respectively. Dr. Gold served as the...

Leadership Team

NamePositionTenureCompensationOwnership
Mitchell Gold
Executive Chairman & CEO7.9yrsUS$2.92m0.019%
€ 791.6k
Stanford Peng
President and Head of Research & Development5.1yrsUS$1.75m0.43%
€ 17.7m
Paul Rickey
Senior VP7.1yrsUS$1.28mno data
Ulrich Fuhs
VP of Finance & Chief Accounting Officerless than a yearno data0.044%
€ 1.8m
M. Yi
Chief Technology Officerless than a yearno datano data
Michelle Greenblatt
Director of Investor Relations & Corporate Communicationsno datano datano data
Remy Durand
Chief Business Officer4.3yrsno data0.15%
€ 6.1m
Andrew Sandler
Chief Medical Officer1.8yrsno datano data

4.3yrs

Average Tenure

52yo

Average Age

Experienced Management: 34LA's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mitchell Gold
Executive Chairman & CEO9.3yrsUS$2.92m0.019%
€ 791.6k
Robert Conway
Independent Director6.8yrsUS$110.21k0.073%
€ 3.0m
James Topper
Independent Director7.9yrsUS$101.46k0%
€ 0
Peter Thompson
Independent Director7.9yrsUS$103.96k0%
€ 0
Rafi Ahmed
Member of Scientific Advisory Board5.5yrsno datano data
Xiangmin Cui
Independent Director5.3yrsUS$100.21k0%
€ 0
Andrew Scharenberg
Scientific Advisory Board Chairmanno datano datano data
Christopher Peetz
Independent Director6.1yrsUS$98.96k0.0028%
€ 113.6k
John Thompson
Member of Scientific Advisory Board5.5yrsno datano data
Manish Butte
Member of Scientific Advisory Boardno datano datano data
Paul Tumeh
Member of Scientific Advisory Boardno datano datano data
James Welsh
Member of Scientific Advisory Board5.5yrsno datano data

6.1yrs

Average Tenure

58yo

Average Age

Experienced Board: 34LA's board of directors are considered experienced (6.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/20 22:53
End of Day Share Price 2024/05/20 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alpine Immune Sciences, Inc. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gao Yi ChenBerenberg
Vamil DivanGuggenheim Securities, LLC
Joseph PantginisH.C. Wainwright & Co.